Cargando…

Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma

INTRODUCTION: The incidence of metastatic squamous cell carcinoma of the anus (SCCA) is increasing. Even if systemic docetaxel, cisplatin, and 5-Fluorouracil (DCF) provide a high rate of long-term remission, the role of pelvic chemoradiation (CRT) is unknown in this setting. We reported the safety a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grave, Athénaïs, Blanc, Julie, De Bari, Berardino, Pernot, Mandy, Boulbair, Fatiha, Noirclerc, Monique, Vienot, Angélique, Kim, Stefano, Borg, Christophe, Boustani, Jihane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354951/ https://www.ncbi.nlm.nih.gov/pubmed/35936677 http://dx.doi.org/10.3389/fonc.2022.918271

Ejemplares similares

Present and Future Research on Anal Squamous Cell Carcinoma
por: Spehner, Laurie, et al.
Publicado: (2021)

Modified DCF (Docetaxel, Cisplatin and 5-fluorouracil) chemotherapy is effective for the treatment of advanced rectal squamous cell carcinoma
por: Hervé, Laure, et al.
Publicado: (2022)

Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Chemoradiation
por: Meunier, Sébastien, et al.
Publicado: (2023)

Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer
por: Robinson, Maxwell, et al.
Publicado: (2020)

Editorial: New understandings and research in anal squamous cell carcinoma
por: Kim, Stefano, et al.
Publicado: (2023)

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
por: Kim, Stefano, et al.
Publicado: (2023)

Long-Term Outcomes of Chemoradiation for Anal Cancer Patients
por: Kim, Hun Jin, et al.
Publicado: (2013)

Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma
por: Thind, Govin, et al.
Publicado: (2014)

Anti-Telomerase CD4(+) Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials
por: Spehner, Laurie, et al.
Publicado: (2020)

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma
por: Kim, Stefano, et al.
Publicado: (2020)

Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?
por: De Bari, Berardino, et al.
Publicado: (2022)

Efficacy and toxicity of chemoradiation in patients with anal cancer - a retrospective analysis
por: Koerber, Stefan Alexander, et al.
Publicado: (2014)

Brachytherapy boost after chemoradiation in anal cancer: a systematic review
por: Frakulli, Rezarta, et al.
Publicado: (2018)

Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancer
por: Rizzo, Alessandro
Publicado: (2022)

Penile Mondor's disease in a patient treated with radical chemoradiation for anal cancer
por: Pittaka, Maria, et al.
Publicado: (2017)

Management of Refractory Metastatic Anal Squamous Cell Carcinoma Following Disease Progression on Traditional Chemoradiation Therapy
por: Silva, Ninoska N., et al.
Publicado: (2012)

Racial disparities in receipt of standard chemoradiation in anal squamous cell carcinoma, an analysis of the National Cancer Database
por: Bian, Shelly X., et al.
Publicado: (2020)

Reply: Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancer
por: Bao, Yongxing, et al.
Publicado: (2022)

Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial
por: Lee, Nancy Y., et al.
Publicado: (2023)

Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial
por: Debernardi, Alice, et al.
Publicado: (2022)

A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer
por: Savoie, Marissa B., et al.
Publicado: (2019)

Patient-Reported Outcomes After Chemoradiation in Patients With Anal Cancer: A Qualitative Analysis
por: Corrigan, Kelsey L., et al.
Publicado: (2022)

Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer
por: Hernandez, Sharia, et al.
Publicado: (2023)

Safety and Efficacy of Stereotactic Body Radiation Therapy for Locoregional Recurrences After Prior Chemoradiation for Advanced Esophageal Carcinoma
por: Seyedin, Steven N., et al.
Publicado: (2020)

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
por: Northover, J, et al.
Publicado: (2010)

Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Diagnosis of Recurrent Anal Cancer After Chemoradiation and Negative Forceps Biopsies: A Case Report
por: LeBlanc, Julia, et al.
Publicado: (2009)

Pelvic collection drainage by Heald anal stent
por: Cook, EJ, et al.
Publicado: (2012)

Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?
por: Guadagni, Stefano, et al.
Publicado: (2017)

Feasibility of accelerated partial breast irradiation with volumetric-modulated arc therapy in elderly and frail patients
por: Riou, Olivier, et al.
Publicado: (2015)

The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
por: Wang, Zhi-Qiang, et al.
Publicado: (2022)

Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma
por: Provencher, Sawyna, et al.
Publicado: (2010)

Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
por: Dewas, Claire Vautravers, et al.
Publicado: (2012)

Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood
por: Boustani, Jihane, et al.
Publicado: (2021)

Cholangiocarcinoma: the quest for a second-line systemic treatment
por: Vienot, Angélique, et al.
Publicado: (2019)

Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution
por: Holliday, Emma B, et al.
Publicado: (2022)

Quantification of tumour heterogeneity and glucose metabolism on pre-chemoradiation PET/CT predicts survival in anal cancer
por: Afaq, A, et al.
Publicado: (2015)

Survival prediction models for patients with anal carcinoma receiving definitive chemoradiation: A population-based study
por: Wu, Yinhang, et al.
Publicado: (2020)

Risk-adjusted chemoradiation according to human papilloma viral status for anal cancer: a pilot study
por: Chu, William, et al.
Publicado: (2023)

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
por: Kim, Stefano, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mad2tqt98eomvp5ciofkpgh823